In short
JNJ-88545223 is an investigational chemical substance being studied for active psoriatic arthritis. It is given as a tablet taken by mouth and has no marketing authorisation in the product records. One Phase 2 trial with 233 participants is registered in the EU Clinical Trials Information System, currently suspended.
Key points
- JNJ-88545223 is an investigational oral tablet for active psoriatic arthritis.
- The registered trial is a Phase 2 study comparing different doses against placebo.
- 233 participants were planned for enrollment.
- The main measure is ACR50 response at Week 16, meaning at least 50% improvement in arthritis signs and symptoms.
- The trial is currently suspended, so no participants are being enrolled at this time.
What is JNJ-88545223?
JNJ-88545223 is an investigational chemical substance, meaning it is a chemically synthesised molecule that has not yet received marketing authorisation as a medicine. It is being developed by Janssen-Cilag International N.V. and is classified under the therapeutic area of immune system diseases. The substance appears in trial records under the single name JNJ-88545223, with no trade name or other development codes listed.
How does JNJ-88545223 work?
The registry data does not describe the mechanism of action of JNJ-88545223. No molecular target or pathway is stated in the available trial records. The substance is being tested in active psoriatic arthritis, a condition where the immune system attacks the joints and skin, but how JNJ-88545223 might affect that process is not explained in the source data.
Which conditions is JNJ-88545223 studied for?
- Active psoriatic arthritis — a form of inflammatory arthritis that affects some people with the skin condition psoriasis, causing joint pain, stiffness and swelling alongside skin symptoms.
How is JNJ-88545223 given?
JNJ-88545223 is formulated as a tablet for oral use, meaning it is taken by mouth. The trial record lists the dose as 0 mg, which indicates that the specific dose levels tested were not reported in the register. The trial compares different doses of JNJ-88545223 against a placebo tablet.
What do the clinical trials show?
One trial of JNJ-88545223 is registered in the EU Clinical Trials Information System under the identifier 2025-523141-10-00. It is a Phase 2 interventional study designed to evaluate how effective and safe different doses of JNJ-88545223 are compared with placebo in people with active psoriatic arthritis.
The trial planned to enroll 233 participants. Its primary outcome is the ACR50 response at Week 16, which measures whether a participant achieves at least a 50% improvement in a standard set of arthritis signs and symptoms defined by the American College of Rheumatology.
The trial is currently suspended, meaning enrollment and treatment are paused. No results from this trial are reported in the registry data.
What side effects are known?
No side effect information for JNJ-88545223 is available in the source data. The registry records do not include safety results or adverse event reports for this substance.